AAPS Pharmaceutical Career News
Mar. 14, 2014

Visit Our Updated AAPS Career Center!

Spring is almost here, which makes this a good time to visit our AAPS Career Center to check out our updated resources as you seek a new position!

If you have any questions, please contact Kevin Folk, Career Services Manager, at folkk@aaps.org.More

Industrial Careers: Big Pharma vs. Biotech?

Many Ph.D. life scientists who have determined that a tenure-track career is not for them set their sights on entry-level research and development (R&D) jobs at pharmaceutical and biotechnology companies. While both pharmaceutical and biotechnology jobs are generally lumped together under the umbrella of “industrial positions,” there are many differences between them. Therefore, to help life scientists considering industrial careers determine which type of job is right for them, it may be useful to review the pros and cons of both types of jobs.

Read more in the March 2014 issue of the AAPS Newsmagazine (member login required).

To become an AAPS Member, contact us today!More

Are Job Boards Dinosaurs Before Their Time?
Job Board Digest
So, you may be thinking that Social Media and specifically LinkedIn are replacing Job Boards – are you? Some of you are thinking this, I bet, and some of you are using LinkedIn today – I’m sure you are. And Job Boards are fee based and LinkedIn is free – right? Wrong! And you’re saying – Kris is bound to say that because he manages a business that is a Job Board. You are right to some extent – however, there is overwhelming evidence worldwide that Job Boards deliver 10 times more candidates to advertised jobs than LinkedIn or any other Social Media platform.More

What Do Pharma's 'High Performers' Have in Common?
PharmExec
A select group of high performing pharma companies are significantly breaking away from the pack in terms of high performance in profitability, growth, future value, consistency and longevity, according to recent biopharmaceutical high performance business research. These high performing pharma companies are able to achieve this by focusing on innovation-driven growth strategies that are substantiated by patient- outcome-focused commercial models. The research looked at the long-term performance of pure play pharma companies — those that have more than 75 per cent of their revenue derived from pharma products.More

Biotechs Are Booming on Wall Street Again — But for How Long?
TIME
If a flood of new startups are rushing into the public market, does it create a bubble? That questions seems to be playing out in the biotech sector, which has gone from years of inattention among investors to a sudden area of interest in the stock market. Last year, 37 biotech companies went public, raising $2.7 billion, according to Renaissance Capital. Both figures easily surpass the totals from the previous five years combined, and even exceed the numbers from the “genomic bubble” year of 2000, when 26 companies raised $1.9 billion.More

10 Key Hourly Employee Prescreening Questions
By Mel Kleiman
Once you have a stack of applications for a job opening, it's best to develop a list of preliminary, prescreening questions to ask promising applicants at the earliest possible stage in your hiring process. You can gather this information on your employment application or by phone to determine whether applicants meet your minimum hiring requirements. This reduces your legal exposure and eliminates any time that would have been wasted in interviews with unsuitable candidates.More

Parexel Connects To Exostar's Life Sciences Cloud Collaboration Platform
Pharmaceutical Business Review
Exostar has announced that Parexel is the latest clinical research organization (CRO) to become a member of Exostar’s rapidly growing Life Sciences community. Parexel provides a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. The company's expertise spans the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology and clinical trials management.More

How do you define success?
By C. Fredrick Crum
When I ask leaders, "How do you define success?" I often get asked, "Are you referring to my professional life, personal life or for this organization?" I often respond asking by this rhetorical question, "How many lives do you have?" Then I let them ponder my question for a few moments. Before they have time to respond, I state, "As far as I know, you only have one life. There are no separate personal and professional lives. Executives do not live some kind of disjointed, separate, bipolar or tripolar lives. There is only life. You cannot separate your personal, professional or organization lives. You only have one life."More

Ohr Pharmaceutical Partners With CSHL to Develop Trodusquemine And Related Analogs
News-Medical
Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs. The new joint venture will be a private entity, initially with equal ownership by Ohr and Cold Spring Harbor Laboratory.More

Is Pharmaceutical Biotech Investment At Risk?
By Mike Wokasch
OK. I'm not an analyst, at least not the certified financial type, but I believe there is a very disconcerting trend evolving in the financial markets. I wrote about this previously but I limited my attention at the time to startup biotech funding. I now feel the issue may have a profound effect on all Big Pharma and biotech. What am I talking about? Investor obsession with short term quick returns. Perhaps this isn't new, but it is certainly heightened in seriousness with the recent Facebook acquisition of WhatsApp, which also highlights why this trend is likely to continue.More

A Finger On The Corporate Pulse
The Wall Street Journal
Freda Lewis-Hall, chief medical officer at Pfizer Inc., has a pretty basic mission: She tries to make sure that patients are getting the right medicine the right way. Much of her work involves leading the company medical specialists who give information to, and answer questions from, doctors, pharmacists and nurses about Pfizer drugs. She also makes sure that patients understand what pills they're taking. Such efforts have taken Dr. Lewis-Hall onto television shows and into experimenting with an Internet health site and with YouTube videos. She also helps forge research collaborations between Pfizer and patient groups and the National Institutes of Health.More